BioLineRx is a biopharmaceutical development company focused on building a portfolio of products to address unmet medical needs or offer advantages over currently available therapies. The company’s portfolio presently consists of six clinical stage candidates,…
SciClone Pharmaceuticals is a specialty pharmaceutical company with its primary focus in China. The company’s product portfolio includes therapies for oncology, infectious diseases and disorders of the cardiovascular, urological, respiratory and central nervous systems. Headquartered…
Orexigen Therapeutics, a biopharmaceutical company, is focused on treating obesity. Contrave, Orexigen’s lead product candidate, has completed Phase III clinical trials, and a New Drug Application has been submitted and reviewed by the U.S. Food…
As long as there have been human conflicts, there has been spying, the penetration of secrecy to discover the plans and tools of the other side. For most of history, spying was based almost exclusively…
Immunovaccine is a clinical-stage vaccine development company focused on the advancement of its patented DepoVax vaccine adjuvanting platform and product candidates for cancer therapy, infectious disease and animal health. Demonstrating safety and immunogenicity potential, Immunovaccine…
iCo Therapeutics is a re-profiling company engaged in re-dosing or reformulating drugs with clinical history for new or expanded indications. The company owns the global rights to three products: iCo-007, currently in a Phase I…
BioDelivery Sciences International is a specialty pharmaceutical company leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize new applications of proven therapeutics – either independently or in partnerships with third parties.…
Oragenics is dedicated to becoming a global leader in probiotics for oral health in humans and pets and in novel antibiotics against infectious disease. The company is engaged in developing, marketing and selling proprietary probiotics…
Arena Pharmaceuticals is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs for weight management, cardiovascular disease, inflammation and other disorders. The company’s internally discovered drug, BELVIQ (lorcaserin HCI), was approved…
Alkermes is a fully integrated, worldwide biopharmaceutical company focused on applying its scientific expertise and proprietary technologies in the development of innovative medicines to improve patient outcomes. Headquartered in Dublin, Ireland, the company has a…
OncoGenex Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing new therapies to address treatment resistance in cancer patients. Each product candidate in the company’s diverse oncology pipeline has a distinct mechanism of action…
pSivida is engaged in developing tiny, sustained-release drug delivery products created to deliver drugs at a controlled or steady rate for months or years. The company is currently focused on treating chronic diseases of the…
Sucampo Pharmaceuticals is a worldwide pharmaceutical company engaged in the innovative research, discovery, development and commercialization of proprietary drugs based on prostones. Sucampo Chairman, CEO and Co-founder Ryuji Ueno, M.D., Ph.D., was the first person…
Regulus Therapeutics is a biopharmaceutical company at the forefront of discovering and developing innovative medicines that target microRNAs. Leveraging a mature therapeutic platform that is based on technology developed over 20 years, the company is…
StemCells is engaged in the research, development, and commercialization of cell-based therapeutics for use in stem-cell based research and drug discovery. The company’s lead therapeutic product candidate, HuCNS-SC cells, is currently in development as a…
Protalix BioTherapeutics is a biopharmaceutical company engaged in developing and commercializing recombinant therapeutic proteins expressed through ProCellEx, a proprietary plant cell-based expression system. Using ProCellEx, the company is developing and commercializing a proprietary pipeline of…
Astex Pharmaceuticals is a pharmaceutical company focused on the discovery and development of novel small molecule therapeutics, with a focus on oncology. The company is currently engaged in developing a proprietary pipeline of novel therapies…
NanoViricides is a development-stage company engaged in creating special purpose nanomaterials for antiviral therapy. The company’s novel nanoviricide class of drug candidates is designed for the specific purpose of attacking and dismantling enveloped virus particles.…
Prima BioMed is a biotechnology that is active throughout the world. A leader in personalized bio-therapeutic cancer products, the company is focused on leveraging its current technology and expertise in developing innovative treatment options for…
Injectable drug delivery systems developer and commercial supplier Unilife Corporation has announced the completion of the sale of common stocks and warrants for gross proceeds totaling $10 million. This has been achieved under a registered…
Synthetic Biologics is a biotechnology company developing product candidates for serious infections and diseases. The company is developing a biologic for preventing C. diff infection as well as a series of monoclonal antibodies (mAbs) for…
DURECT is a specialty pharmaceutical company focused on developing innovative drugs for pain and chronic diseases, with late-stage development programs including REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil. The company’s proprietary oral, transdermal and injectable depot delivery…
Tengion is a leading clinical-stage regenerative medicine company focused on the development of its pioneering Organ Regeneration Platform. This platform is intended to harness the body’s intrinsic regenerative pathways to regenerate an array of native-like…
Tekmira Pharmaceuticals is a biopharmaceutical company and a leader in developing RNA interference (RNAi) therapeutics. The company is focused on advancing novel RNAi therapeutics and supplying pharmaceutical partners with its leading lipid nanoparticle delivery technology.…
Nymox Pharmaceutical is focused on researching and developing novel drugs and diagnostic products for the aging population. NX-1207, the company’s lead drug candidate, is a proprietary treatment for enlarged prostate or benign prostatic hyperplasia (BPH)…
ADVENTRX Pharmaceuticals is a biopharmaceutical company engaged in the development of proprietary product candidates for treating various diseases and conditions. ANX-188, the company’s lead product candidate, is initially being developed as a treatment for complications…
ACADIA Pharmaceuticals is a biopharmaceutical company with its focus on innovative treatments addressing unmet medical needs in neurological and related central nervous system disorders. Pimavanserin, which is in Phase III clinical development as a potential…
ZIOPHARM Oncology is a biopharmaceutical company engaged in developing and commercializing new cancer therapies. The company’s clinical programs include palifosfamide, currently being studied in two Phase 3 clinical trials; Ad-RTS IL-12, currently being tested in…
Apricus Biosciences is a biopharmaceutical company engaged in developing and marketing innovative treatments to help large patient populations across numerous high-demand therapeutic classes, including male and female sexual health. With three approved products, the company…
Today before the opening bell, Cardium Therapeutics announced that the American Podiatric Medical Association (APMA) has granted its prestigious Seal of Approval to Excellagen®, Cardium’s advanced, FDA-cleared wound care product, for improving foot health and…
Affymax is a Palo Alto, Calif.-based biopharmaceutical company. The company’s focus is on discovering, developing and delivering innovative therapies to improve the lives of patients suffering with kidney disease and other serious, often life-threatening illnesses.…
Cempra is a clinical-stage pharmaceutical company engaged in developing antibiotics to meet critical needs in treating bacterial infectious diseases. The company’s two lead product candidates, solithromycin and CEM-102, are currently in advanced clinical development –…
Inovio Pharmaceuticals is revolutionizing vaccines for the prevention and treatment of today’s cancers and infectious diseases. The company’s SynCon vaccines are designed to provide universal cross-strain protection against both known and newly emergent unmatched strains…
Neuralstem possesses patented technology that enables the production of neural stem cells of the human brain and spinal cord in commercial quantities, as well as the ability to control the differentiation of these cells into…
Resverlogix is a clinical-stage cardiovascular company with an epigenetic platform technology that modulates protein production. The company is currently developing RVX-208, which is a first-in-class small molecule for treating atherosclerosis and the first BET bromodomain…
Athersys is a clinical stage biopharmaceutical company focused on discovering and developing therapeutic product candidates for extending and enhancing human quality of life. The company is currently developing its MultiStem cell therapy product and has…
ImmunoGen is a biotechnology company developing targeted anticancer therapeutics using its Targeted Antibody Payload (TAP) technology, coupled with its expertise in monoclonal antibodies and tumor biology. A TAP compound delivers one of ImmunoGen’s purpose-developed cancer-killing…
Zalicus is a biopharmaceutical company engaged in discovering and developing novel treatments for patients suffering with pain. The company’s portfolio of proprietary clinical-stage product candidates has entered into various revenue-generating collaborations with large pharmaceutical companies…
Verint Systems announced that Honda Canada Finance, a customer of Verint, has won the company’s “Contact Center Excellence” Leadership Award for 2012. The award was bestowed to Honda Canada due to their use of Verint’s…
Yesterday, MEI Pharma announced that it has appointed Thomas C. Reynolds, M.D., Ph.D., to its Board of Directors. An industry veteran, Dr. Reynolds brings over 20 years of oncology drug development experience to MEI, including…